FDA Grants Breakthrough Therapy Designation to Emiltatug Ledadotin for Adenoid Cystic Carcinoma — Rare Salivary Gland Cancer With No Approved Targeted Therapies

The FDA granted Breakthrough Therapy Designation (BTD) to emiltatug ledadotin (Emi-Le) for locally advanced, recurrent, or metastatic adenoid cystic carcinoma (ACC) with solid histology or high-grade transformation. The designation was supported by Phase 1 multicenter clinical trial data across ACC, triple-negative breast cancer, and other solid tumors. Adenoid cystic carcinoma is a rare, aggressive malignancy most commonly arising in the salivary glands — characterized by a deceptively indolent growth pattern punctuated by relentless progression and late distant metastases, most frequently to the lungs, where the disease becomes essentially incurable. There are currently no FDA-approved targeted therapies specifically for ACC, making BTD status for emiltatug ledadotin a critical development for this rare cancer community. Emiltatug ledadotin is an antibody-drug conjugate (ADC) targeting a tumor-associated cell-surface antigen expressed on ACC cells, combining antibody precision with cytotoxic payload delivery. Breakthrough Therapy Designation is granted to expedite development and review of drugs for serious conditions when preliminary clinical evidence indicates substantial improvement over available therapy — in ACC's case, where no targeted options exist, the bar for BTD reflects the acute unmet need. Additional Phase 1/2 trial enrollment is ongoing in ACC and related salivary gland malignancies.